Tiziana Life Sciences (TLSA) advances TZLS-501 as second asset

Rhea-AI Filing Summary

Tiziana Life Sciences used this Form 6-K to announce that it will advance TZLS-501, its second asset, a fully human anti-IL-6 receptor monoclonal antibody. The company highlights rising interest in the IL-6 pathway, noting Novartis’ approximately $1.4 billion acquisition of Tourmaline Bio as an example of recent industry activity. Tiziana plans to pursue non-dilutive funding strategies to develop TZLS-501, meaning it is looking for ways to fund the program without issuing new equity. At the same time, the company will continue to advance intranasal foralumab as its lead program.

Insights

Biotech pipeline and strategy analyst

Tiziana adds a second IL-6 pathway asset while keeping foralumab as its lead program.

Tiziana Life Sciences is moving forward with TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody, as its second asset. This broadens the company’s pipeline beyond its existing focus on intranasal foralumab, which remains the lead program. The move is framed against increased industry activity in the IL-6 pathway, including Novartis’ approximately $1.4 billion acquisition of Tourmaline Bio.

The company states it will pursue non-dilutive funding strategies for TZLS-501, indicating a preference for development capital that does not require issuing new equity or similar dilution sources. Actual impact on shareholders will depend on what specific funding structures, partnerships, or transactions are ultimately secured, which are not detailed here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 25, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ (NYSE: NVS) recent acquisition of Tourmaline Bio (Nasdaq: TRML) for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 25, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 25, 2025

3

FAQ

What did Tiziana Life Sciences (TLSA) announce in this Form 6-K?

Tiziana Life Sciences announced that it will advance TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody, as its second asset while keeping intranasal foralumab as its lead program.

What is TZLS-501 in Tiziana Life Sciences' pipeline?

TZLS-501 is described as a fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, which Tiziana is advancing as its second asset alongside its lead intranasal foralumab program.

How does Tiziana Life Sciences plan to fund development of TZLS-501?

The company states it will pursue non-dilutive funding strategies for the development of TZLS-501, seeking capital sources that do not require issuing new equity.

What industry context does Tiziana provide around the IL-6 pathway?

Tiziana notes heightened industry activity in the IL-6 pathway space, highlighting Novartis’ acquisition of Tourmaline Bio for approximately $1.4 billion as an example.

Does this filing change Tiziana Life Sciences' lead program?

No. The company states it will continue to advance intranasal foralumab as its lead program while adding TZLS-501 as a second asset.

What document is attached to this Tiziana Life Sciences Form 6-K?

The Form 6-K includes as Exhibit 99.1 a Tiziana Life Sciences press release dated September 25, 2025, which provides the related announcement.